Pfizer Stock: How to Trade the Latest Price Action
Dec 8, 2021
Shares in Pfizer (PFE) saw two-sided action this week after news surfaced that three doses of its Covid-19 vaccine show promising results against the Omicron variant.
Pfizer continues to outpace the S&P Healthcare (XLV), with returns almost double that of the sector.
Regarding trading opportunity, Pfizer now has an implied volatility rank of 73, with a raw implied volatility of 39%, more than twice that of the sector ETF.
Trader’s may be hesitant of picking a price direction in Pfizer given its meteoric rise this year and the possibility for major Covid media developments to jolt the stock one way or another. Options traders can overcome this analysis paralysis by utilizing strategies that could profit regardless of price direction.
Today’s Alpha Boost email from Quiet Foundation included two strategies that could fit this mentality. The first is a put ratio spread, combining one long put option with two short put options to create a position that is net bullish (positive delta) but could profit more from a fall in the stock price.
The 50 / 49 put ratio (buying the 50 put and selling two 49 puts) collects $104 in premium but could profit as much as $204 of the stock price falls to $49 by expiration. While the trade is short two put options, the long option at a higher strike creates a debit spread resulting in the net risk of only one put.
Similar to the ratio spread, the put broken wing butterfly could be profitable in all three scenarios of price direction. The butterfly adds another long put option, capping the risk on the trade.
This trade idea is the same as the ratio above but adds the purchase of the 46 put to make the maximum loss on the trade $161, while lowering the premium to $39 and the max profit to $139. Again, the maximum profit would only be realized if PFE is at $49 at January expiration.
Traders interested in other stocks related to vaccine treatments could look for opportunities in Covid-19 drug makers could look into Moderna (MRNA) or Merck (MRK) which respectively produce vaccines and antiviral drugs. It’s worth noting that Pfizer makes up 5.7% of the portfolio held by XLV, while Merck constitutes 3.6% and Moderna 1.9%.
Options involve risk and are not suitable for all investors. Please read Characteristics and Risks of Standardized Options before deciding to invest in options.
tastylive content is created, produced, and provided solely by tastylive, Inc. (“tastylive”) and is for informational and educational purposes only. It is not, nor is it intended to be, trading or investment advice or a recommendation that any security, futures contract, digital asset, other product, transaction, or investment strategy is suitable for any person. Trading securities, futures products, and digital assets involve risk and may result in a loss greater than the original amount invested. tastylive, through its content, financial programming or otherwise, does not provide investment or financial advice or make investment recommendations. Investment information provided may not be appropriate for all investors and is provided without respect to individual investor financial sophistication, financial situation, investing time horizon or risk tolerance. tastylive is not in the business of transacting securities trades, nor does it direct client commodity accounts or give commodity trading advice tailored to any particular client’s situation or investment objectives. Supporting documentation for any claims (including claims made on behalf of options programs), comparisons, statistics, or other technical data, if applicable, will be supplied upon request. tastylive is not a licensed financial adviser, registered investment adviser, or a registered broker-dealer. Options, futures, and futures options are not suitable for all investors. Prior to trading securities, options, futures, or futures options, please read the applicable risk disclosures, including, but not limited to, the Characteristics and Risks of Standardized Options Disclosure and the Futures and Exchange-Traded Options Risk Disclosure found on tastytrade.com/disclosures.
tastytrade, Inc. ("tastytrade”) is a registered broker-dealer and member of FINRA, NFA, and SIPC. tastytrade was previously known as tastyworks, Inc. (“tastyworks”). tastytrade offers self-directed brokerage accounts to its customers. tastytrade does not give financial or trading advice, nor does it make investment recommendations. You alone are responsible for making your investment and trading decisions and for evaluating the merits and risks associated with the use of tastytrade’s systems, services or products. tastytrade is a wholly-owned subsidiary of tastylive, Inc.
tastytrade has entered into a Marketing Agreement with tastylive (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade. tastytrade and Marketing Agent are separate entities with their own products and services. tastylive is the parent company of tastytrade.
tastycrypto is provided solely by tasty Software Solutions, LLC. tasty Software Solutions, LLC is a separate but affiliate company of tastylive, Inc. Neither tastylive nor any of its affiliates are responsible for the products or services provided by tasty Software Solutions, LLC. Cryptocurrency trading is not suitable for all investors due to the number of risks involved. The value of any cryptocurrency, including digital assets pegged to fiat currency, commodities, or any other asset, may go to zero.